IMMUNOlogical microenvironment in REctal Adenocarcinoma Treatment (IMMUNOREACT 2; NCT04917263): preliminary results on prediction of complete response to neoadjuvant therapy in rectal cancer
Gaya Spolverato(University of Padua), Marco Scarpa(University of Padua), Ignazio Castagliuolo(University of Padua), Melania Scarpa(University of Padua), Cesare Ruffolo(Ca' Foncello Hospital), Marco Massani(AULSS 2 Marca Trevigiana), Valentina Chiminazzo(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Matteo Fassan(University of Padua), Fabrizio Vittadello(University of Padua), Pierluigi Pilati(Istituto Oncologico Veneto), Alice Bressan(Ospedale Sant Antonio), Luca Facci(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Giovanni Pirozzolo(Ottawa Hospital), Imerio Angriman, Andrea Porzionato(University of Padua), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Salvatore Pucciarelli(Azienda Ospedale - Università Padova)
Cited by 0
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Reversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and Octreotide
|Hepatology|1999|560
Toll-Like Receptor 2 Regulates Intestinal Inflammation by Controlling Integrity of the Enteric Nervous System
|Gastroenterology|2013|296
cT3N0 Rectal Cancer: Potential Overtreatment With Preoperative Chemoradiotherapy Is Warranted
|Journal of Clinical Oncology|2008|266